Ipilimumab: all 592 studies that test it
Page 5 of 6. Open to participants first (76), then studies with results posted, then the rest; newest registration first within each.
- Neoadjuvant Immune Checkpoint Blockade in Resectable Malignant Pleural MesotheliomaActive, not recruitingNCT03918252Phase 2
- A Trial of Immunotherapy Strategies in Metastatic Hormone-sensitive Prostate CancerStatus unknownNCT03879122Phase 2/3
- Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME TrialTerminatedNCT03878524Phase 1
- A Study of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Participants With Advanced Kidney CancerActive, not recruitingNCT03873402Phase 3
- Study of Tilsotolimod in Combination With Nivolumab and Ipilimumab for the Treatment of Solid Tumors (ILLUMINATE-206)Active, not recruitingNCT03865082Phase 2
- NIVOLUMAB Plus IPILIMUMAB and TEMOZOLOMIDE in Microsatellite Stable, MGMT Silenced Metastatic Colorectal CancerCompletedNCT03832621Phase 2
- An Open-label, Randomized, Parallel, Non Comparative, Phase II Trial of Nivolumab Plus Ipilimumab Versus Platinum-based Chemotherapy Plus Nivolumab in Chemonaive Metastatic or Recurrent Squamous-Cell Lung Cancer (SqLC)Status unknownNCT03823625Phase 2
- Evaluate the Clinical Benefit of a Post-operative Treatment Associating Radiotherapy + Nivolumab + Ipilimumab Versus Radiotherapy + Capecitabine for Triple Negative Breast Cancer Patients With Residual DiseaseActive, not recruitingNCT03818685Phase 2
- Testing the Combination of Anetumab Ravtansine With Either Nivolumab, Nivolumab and Ipilimumab, or Gemcitabine and Nivolumab in Advanced Pancreatic CancerActive, not recruitingNCT03816358Phase 1
- Nivolumab, Ipilimumab and OTSGC-A24 Therapeutic Peptide Vaccine in Gastric Cancer - a Combination Immunotherapy Phase Ib Study.Status unknownNCT03784040Phase 1
- Nivolumab, Ipilimumab and Chemoradiation in Treating Patients With Resectable Gastric CancerActive, not recruitingNCT03776487Phase 2
- VX15/2503 With or Without Ipilimumab and/or Nivolumab in Patients With Resectable Stage IIIB-D MelanomaActive, not recruitingNCT03769155Phase 1
- Evaluation of Safety and Efficacy of Patients With Four and More Symptomatic Brain Metastases of MelanomaTerminatedNCT03728465Phase 2
- VX15/2503 in Combination With Ipilimumab or Nivolumab in Patients With Head and Neck CancerActive, not recruitingNCT03690986Phase 1
- Nivolumab, Ipilimumab, and Bicalutamide in Human Epidermal Growth Factor (HER) 2 Negative Breast Cancer PatientsActive, not recruitingNCT03650894Phase 2
- Modified FOLFOX Plus/Minus Nivolumab and Ipilimumab vs. FLOT Plus Nivolumab in Patients With Previously Untreated Advanced or Metastatic Gastric CancerCompletedNCT03647969Phase 2
- A Randomized Phase II Study on the Optimization of Immunotherapy in Squamous Carcinoma of the Head and NeckCompletedNCT03620123Phase 2
- Nivolumab and Ipilimumab in Treating Patients With Esophageal and Gastroesophageal Junction Adenocarcinoma Undergoing SurgerySuspendedNCT03604991Phase 2/3
- Nivolumab and Multi-fraction Stereotactic Radiosurgery With or Without Ipilimumab in Treating Patients With Recurrent Grade II-III MeningiomaActive, not recruitingNCT03604978Phase 1/2
- Nivolumab and Ipilimumab After Donor Stem Cell Transplant in Treating Patients With High Risk Refractory or Relapsed Acute Myeloid Leukemia or Myelodysplastic SyndromeCompletedNCT03600155Phase 1
- A Personal Cancer Vaccine (NEO-PV-01) and APX005M or Ipilimumab With Nivolumab in Patients With Advanced MelanomaTerminatedNCT03597282Phase 1
- Nivolumab +/- Ipilimumab in Patients With Advanced, Refractory Pulmonary or Gastroenteropancreatic Poorly Differentiated Neuroendocrine Tumors (NECs)CompletedNCT03591731Phase 2
- Peri-Operative Immune Checkpoint Inhibition and Cryoablation in Women With Triple-negative Breast CancerActive, not recruitingNCT03546686Phase 2
- Neoantigen DNA Vaccine in Combination With Nivolumab/Ipilimumab and PROSTVAC in Metastatic Hormone-Sensitive Prostate CancerCompletedNCT03532217Phase 1
- Study of Adjuvant Ipilimumab and Nivolumab in Subjects With High-risk Ocular MelanomaActive, not recruitingNCT03528408Phase 2
- Anti-CTLA-4 Antibody Followed by Anti-PD-1 Antibody in Recurrent or Metastatic NSCLCStatus unknownNCT03527251Phase 1
- A Pilot Study Using Short-Term Cultured Anti-Tumor Autologous LymphocytesTerminatedNCT03526185Early Phase 1
- ORIOn-E: A Study Evaluating CPI-1205 in Patients With Advanced Solid TumorsCompletedNCT03525795Phase 1
- A Study of CS1002 in Subjects with Advanced Solid TumorsCompletedNCT03523819Phase 1
- Nogapendekin Alfa Inbakicept for Advanced Non-Small Cell Lung CancerTerminatedNCT03520686Phase 3
- A Study to Test the Safety of Immunotherapy With Nivolumab Alone or With Ipilimumab Before Surgery for Bladder Cancer Patients Who Are Not Suitable for ChemotherapyActive, not recruitingNCT03520491Phase 2
- Nivolumab Plus Ipilimumab as Neoadjuvant Therapy for Hepatocellular Carcinoma (HCC)CompletedNCT03510871Phase 2
- Phase I Multicenter Trial Combining Nivolumab, Ipilimumab and Hypo-fractionated Radiotherapy for Pretreated Advanced Stage Non-small Cell Lung Cancer PatientsTerminatedNCT03509584Phase 1
- Nivolumab With or Without Ipilimumab in Treating Patients With Recurrent or High Grade Gynecologic Cancer With Metastatic Peritoneal CarcinomatosisCompletedNCT03508570Phase 1
- Testing the Combination of Copanlisib, Nivolumab and Ipilimumab in Patients With Advanced Cancer and LymphomaActive, not recruitingNCT03502733Phase 1
- Stereotactic Body Radiation Therapy With REGN2810 and/or Ipilimumab Before Surgery in Treating Participants With Progressive Advanced or Oligometastatic Prostate CancerWithdrawnNCT03477864Phase 1
- Double Immune Checkpoint Inhibitors in PD-L1-positive Stage IV Non-small Lung CancErCompletedNCT03469960Phase 3
- Immunotherapy + Radiation in Resectable Soft Tissue SarcomaCompletedNCT03463408Early Phase 1
- An Investigational Immunotherapy Study of BMS-986299 Alone and in Combination With Nivolumab and Ipilimumab in Participants With Solid Cancers That Have Spread or Cannot be RemovedTerminatedNCT03444753Phase 1
- Postoperative Immunotherapy vs Standard Chemotherapy for Gastric Cancer With High Risk for RecurrenceActive, not recruitingNCT03443856Phase 2
- Combination of Chemoradiation With Immunotherapy in Inoperable œsophageal CancerTerminatedNCT03437200Phase 2
- Anti-SEMA4D Monoclonal Antibody VX15/2503 With Nivolumab or Ipilimumab in Treating Patients With Stage III or IV MelanomaTerminatedNCT03425461Phase 1
- A Longitudinal Assessment of Tumor Evolution in Patients With Brain CancerCompletedNCT03425292Phase 1
- Neoantigen-based Personalized Vaccine Combined With Immune Checkpoint Blockade Therapy in Patients With Newly Diagnosed, Unmethylated GlioblastomaTerminatedNCT03422094Phase 1
- A Multicenter Open-label Phase II Trial to Evaluate Nivolumab and Ipilimumab for 2nd Line Therapy in Elderly Patients With Advanced Esophageal Squamous Cell CancerCompletedNCT03416244Phase 2
- Ipilimumab or FOLFOX in Combination With Nivolumab and Trastuzumab in HER2 Positive EsophagoGastric AdenocarcinomaCompletedNCT03409848Phase 2
- Phase IIb Study Evaluating Immunogenic Chemotherapy Combined with Ipilimumab and Nivolumab in Breast CancerCompletedNCT03409198Phase 2
- CAVATAK® and Ipilimumab in Uveal Melanoma Metastatic to the Liver (VLA-024 CLEVER)CompletedNCT03408587Phase 1
- A Dose-Escalation Study of MDX-010 Administered Monthly as Immunotherapy in Subjects Infected With Human Immunodeficiency Virus (HIV)CompletedNCT03407105Phase 1
- Neo-Adjuvant Bladder Urothelial Carcinoma COmbination-immunotherapyCompletedNCT03387761Phase 1
- VX15/2503 and Immunotherapy in Resectable Pancreatic and Colorectal CancerCompletedNCT03373188Phase 1
- BrUOG 354 Nivolumab +/- Ipilimumab for Ovarian and Extra-renal Clear Cell CarcinomasActive, not recruitingNCT03355976Phase 2
- Nivolumab and Ipilimumab Versus Chimiotherapy in First Line Treatment in PS 2 or Elderly in Advanced NSCLC PatientsCompletedNCT03351361Phase 3
- Combination of Nivolumab and Ipilimumab in Breast, Ovarian and Gastric Cancer PatientsTerminatedNCT03342417Phase 2
- An Adaptive Study to Match Patients With Solid Tumors to Various Immunotherapy Combinations Based Upon a Broad Biomarker AssessmentCompletedNCT03335540Phase 1
- Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary TumorsActive, not recruitingNCT03333616Phase 2
- Glembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced Metastatic Solid Tumors That Cannot Be Removed by SurgeryWithdrawnNCT03326258Phase 1/2
- Nivolumab With and Without Ipilimumab and Radiation Therapy in Treating Patients With Recurrent or Resectable Undifferentiated Pleomorphic Sarcoma or Dedifferentiated Liposarcoma Before SurgeryActive, not recruitingNCT03307616Phase 2
- Nivolumab/Ipilimumab-Primed Immunotransplant for DLBCLCompletedNCT03305445Phase 1
- Nivolumab in Combination With Ipilimumab in Patients With Metastatic Renal Cell CarcinomaCompletedNCT03297593Phase 2
- Radiation Therapy With Combination Immunotherapy for Relapsed/Refractory Metastatic MelanomaWithdrawnNCT03297463Phase 1/2
- Study of Lenalidomide/Dexamethasone With Nivolumab and Ipilimumab in Patients With Newly Diagnosed Multiple MyelomaWithdrawnNCT03283046Phase 1
- A Study of Carboplatin and Paclitaxel Chemotherapy With Nivolumab With or Without Ipilimumab in Patients With Ovarian CancerCompletedNCT03245892Phase 1
- Ipilimumab and Nivolumab as Adjuvant Treatment of Mucosal MelanomaStatus unknownNCT03241186Phase 2
- A Phase I/II Clinical Trial on the Per-operative Intratumoral Administration of Myeloid Dendritic Cells Plus Ipilimumab and Nivolumab, Followed by Repeated Intracavitary Plus Intravenous Administration of Nivolumab in Patients With Recurrent Glioblastoma.Active, not recruitingNCT03233152Phase 1/2
- Concurrent or Sequential Immunotherapy and Radiation Therapy in Patients With Metastatic Lung CancerActive, not recruitingNCT03223155Phase 1
- Nivolumab and Ipilimumab in Classical Kaposi Sarcoma (CKS)Status unknownNCT03219671Phase 2
- A Safety Study of Lirilumab in Combination With Nivolumab or in Combination With Nivolumab and Ipilimumab in Advanced and/or Metastatic Solid TumorsCompletedNCT03203876Phase 1
- Stereotactic Body Radiotherapy (SBRT) Followed by Immunotherapy in Liver CancerTerminatedNCT03203304Phase 1
- Phase II Sequential Treatment Trial of Single Agent Nivolumab, Then Combination Ipilimumab + Nivolumab in Metastatic or Unresectable Non-Clear Cell Renal Cell Carcinoma (ANZUP1602)Status unknownNCT03177239Phase 2
- Nivolumab, Ipilimumab, and Radiation Therapy in Treating Patients With Stage III-IVB Head and Neck CancerCompletedNCT03162731Early Phase 1
- Evaluation of Denosumab in Combination With Immune Checkpoint Inhibitors in Patients With Unresectable or Metastatic MelanomaStatus unknownNCT03161756Phase 1/2
- A Study of Combination with TBI-1401(HF10) and Ipilimumab in Japanese Patients with Unresectable or Metastatic MelanomaCompletedNCT03153085Phase 2
- Investigator-Initiated Trial of Combined Ipilimumab, Nivolumab and Stereotactic Radiation in Patients With Metastatic Clear-Cell RCC (ccRCC) Who Have Failed Treatment With Single-Agent NivolumabWithdrawnNCT03149159Phase 2
- SAbR Plus Ipilimumab Plus Nivolumab in Metastatic Melanoma PatientsWithdrawnNCT03126461Phase 2
- Intermittent Therapy in Metastatic Renal Cell Carcinoma Patients Treated With Ipilimumab and NivolumabCompletedNCT03126331Phase 2
- A Study to Evaluate Adaptive Dosing of Ipilimumab and Nivolumab Combination ImmunotherapyActive, not recruitingNCT03122522Phase 2
- Nivolumab and Ipilimumab and Radiation Therapy in MSS and MSI High Colorectal and Pancreatic CancerActive, not recruitingNCT03104439Phase 2
- Immunotherapy Study of Evofosfamide in Combination With IpilimumabStatus unknownNCT03098160Phase 1
- Phase 2 Trial of Ipilimumab and Nivolumab in Nasopharyngeal CarcinomaActive, not recruitingNCT03097939Phase 2
- Study of Nivolumab Verses Nivolumab and Ipilimumab Combination in EGFR Mutant Non-small Cell Lung CancerTerminatedNCT03091491Phase 2
- BIOLUMA: Biomarkers for Nivolumab and Ipilimumab and Evaluation of the Combination in Lung CancerCompletedNCT03083691Phase 2
- Autologous CD8+ SLC45A2-Specific T Lymphocytes With Cyclophosphamide, Aldesleukin, and Ipilimumab in Treating Patients With Metastatic Uveal MelanomaActive, not recruitingNCT03068624Phase 1
- Nivolumab and Ipilimumab Treatment in Prostate Cancer With an Immunogenic SignatureActive, not recruitingNCT03061539Phase 2
- Ipilimumab and Nivolumab in the Treatment of Malignant Pleural MesotheliomaCompletedNCT03048474Phase 2
- A Safety Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Non-small Cell Lung CancerWithdrawnNCT03048136Phase 3
- ImmunoModulation by the Combination of Ipilimumab and Nivolumab Neoadjuvant to Surgery In Advanced or Recurrent Head and Neck CarcinomaCompletedNCT03003637Phase 1/2
- A Phase II of Nivolumab Plus Ipilimumab in Non-resectable Sarcoma and Endometrial CarcinomaStatus unknownNCT02982486Phase 2
- Immunization Strategy With Intra-tumoral Injections of Pexa-Vec With Ipilimumab in Metastatic / Advanced Solid Tumors.CompletedNCT02977156Phase 1
- Optimal Neo-adjuvant Combination Scheme of Ipilimumab and NivolumabActive, not recruitingNCT02977052Phase 2
- A BIOmarker Driven Trial With Nivolumab and Ipilimumab or VEGFR tKi in Naïve Metastatic Kidney CancerCompletedNCT02960906Phase 2
- NeoVax Plus Ipilimumab in Renal Cell CarcinomaActive, not recruitingNCT02950766Phase 1
- A Clinical Trial: Adjuvant Low-dose Ipilimumab + Nivolumab After Resection of Melanoma MacrometastasesCompletedNCT02941744Phase 1/2
- Selective HDAC6 Inhibitor ACY-241 in Combination With Ipilimumab and NivolumabCompletedNCT02935790Phase 1
- A Phase II Trial of Ipilimumab and Nivolumab for the Treatment of Rare CancersCompletedNCT02923934Phase 2
- Yttrium90, Ipilimumab, & Nivolumab for Uveal Melanoma With Liver MetastasesStatus unknownNCT02913417Phase 1/2
- Nivolumab With or Without Ipilimumab in Treating Patients With Gastrointestinal Stromal Tumor That Is Metastatic or Cannot Be Removed by SurgeryCompletedNCT02880020Phase 2
- Immune Checkpoint Inhibition in Combination With Radiation Therapy in Pancreatic Cancer or Biliary Tract Cancer PatientsCompletedNCT02866383Phase 2
- Single Agent and Combined Inhibition After Allogeneic Stem Cell TransplantTerminatedNCT02846376Phase 1
- Nivolumab and Ipilimumab in Treating Patients With Rare TumorsActive, not recruitingNCT02834013Phase 2